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Background: Hereditary diffuse gastric cancer (HDGC) is a hereditary autosomal inherited syndrome associated
with CDH1 germline mutations. In Brazil, gastrointestinal tumors are among the most prevalent tumor types and
constitute a serious public health problem, especially in the northern and northeastern regions. This study aimed to
investigate germline mutations, methylation pattern and genomic rearrangements in the CDH1 gene and quantitative
changes in the DNA of HDGC patients in northern and northeastern Brazil.
Methods: Twenty-seven DNA samples from the members of four families affected by HDGC were analyzed using array
comparative genomic hybridization (aCGH), DNA sequencing and methylation pattern.
Results: No evidence of gain and loss events or any rearrangements were found in any of the samples tested using
aCGH. No promoter region hypermethylation was observed either. Two of the four families presented different types of
germline mutations. The 185G > T and 1018A > G germline mutations detected in this study have been described in
Asian and European families, respectively. The ancestors of the two families carrying these mutations had originated
from those continents.
Conclusion: This is the first study to evaluate CDH1 gene germline mutations in Brazilian families with HDGC. In our
study, 50% of the families showed no CDH1 gene alterations, and it is possible that in regions with a high incidence of
gastric cancer, such as northern and northeastern Brazil, environmental factors might have induced the different
genetic alterations analyzed in this study.
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In northern and northeastern Brazil, gastric cancer (GC)
is the second most common type of cancer and is
considered a serious public health problem because it is
usually diagnosed at an advanced stage [1]. In addition
to its sporadic manifestation, GC is also associated with
various syndromes that predispose the carrier to cancer.
Among the familial forms of GC, hereditary diffuse gastric* Correspondence: caroline@ufpa.br
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article, unless otherwise stated.cancer (HDGC) is the only form with a well-defined genetic
cause [2,3].
In order for a family to qualify for a diagnosis of
HDGC, the following criteria must be met: two or more
documented cases of diffuse gastric cancer in first- or
second-degree relatives with at least one diagnosed before
the age of 50 years or three or more cases of documented
diffuse gastric cancer in first- or second-degree relatives
independent of the age of onset [4,5].
The correlation between an E-cadherin gene germline
mutation (CDH1 inactivation) and the predisposition to
diffuse gastric cancer was first identified in a large family
in New Zealand [6]. Based on this finding, HDGC wasCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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patients with different ethnic backgrounds [7,8].
The CDH1 gene, located on the 16q22.1 chromosome,
encodes the E-cadherin intercellular adhesion protein; this
protein acts as a tumor suppressor and plays an important
role in maintenance of the epithelial tissue architecture
[9]. Mutations in this gene primarily affect both the intra-
cellular and extracellular domains of the protein and thus
affect the integrity of the protein, leading to disturbances
in epithelial tissue cell-cell adhesion, increased cell mo-
tility and an enhanced infiltrative capacity and tumor
metastasis [10,11]. As HDGC is an infiltrative tumor,
endoscopy and biopsy-based diagnostic strategies are in-
efficient; furthermore, given the high penetrance of CDH1
mutations, prophylactic gastrectomy is recommended for
affected patients [11,12].
Over one hundred germline mutations have been de-
scribed for the CDH1 gene. Although several of these
mutations have been detected in different families, to
date, no hotspot has been characterized [3,13]. Although
the CDH1 gene is the predominantly affected gene in
HDGC, other inactivation mechanisms should be in-
vestigated. Additionally, large deletions might also be
responsible for CDH1 inactivation [8,14-20]. For this
reason, an array comparative genomic hybridization
(aCGH) analysis is essential to the identification of
quantitative alterations in the CDH1 gene or other genome
regions in families affected by HDGC [21].
The objective of this study was to identify germline
mutations in the CDH1 gene and/or quantitative genomic




The samples evaluated in this study were obtained from
patients who fulfilled the clinical criteria according to
the latest consensus of the International Gastric Cancer
Linkage Consortium [5]. The patients had been treated
at referral hospitals in northern and northeastern Brazil.
The samples were processed in their states of origin and
then sent to the Federal University of Pará (Universidade
Federal do Pará; UFPA) for genetic analysis.
A retrospective study of the family members was also
conducted to identify previous generations with DGC.
All genetically analyzed patients (or their guardians)
signed consent forms that had been approved by the
Research Ethics Committee of University Hospital João
de Barros Barreto (Hospital Universitário João de
Barros Barreto; HUJBB) under protocol number 274/
12. Assurance was provided that the use of biological
materials and participation in the study would not
cause any harm to nor have any negative influence on
patient treatment.All biological materials except one sample (that was
Formaldehyde Fixed-Paraffin Embedded tissue) was blood
DNA. And all genetic screening analysis - mutation,
deletion and methylation - were all looking for germline
changes, not somatic.
DNA extraction
Peripheral blood samples were collected in EDTA-
containing tubes and extracted with the QIAamp® DNA
Blood Mini Kit (Qiagen N.V., Venlo, The Netherlands) ac-
cording to the manufacturer’s instructions.
Paraffin block sample was obtained from one patient,
and extracted with the QIAamp DNA® FFPE Tissue Kit
(Qiagen) according to the manufacturer’s instructions.
Genotypic analysis
The obtained DNA was used to perform molecular
screening of the CDH1 gene. Gene fragments containing
the analyzed polymorphisms were amplified by polymer-
ase chain reaction (PCR) using gene-specific reaction con-
ditions and primers (Table 1) according to Brooks-Wilson
et al. [22].
The result of each reaction was subjected to direct
sequencing on an ABI 3130 capillary sequencing platform
(Applied Biosystems/Life Technologies, Carlsbad, CA,
USA). The sequences were obtained as electropherograms
and analyzed with the software package provided with the
equipment. The generated sequences were analyzed with
the BIQ Analyzer software package [23].
aCGH
High-density probe microarray analyses were performed
to determine the copy number variation (CNV). The
complete genomes of all patients were evaluated with the
goal of identifying genes related to tumor development.
The Affymetrix® CytoScan™ HD Array (Affymetrix,
Inc., Santa Clara, CA, USA) was used; this system features
a total of approximately 1.9 million probes for detecting
CNV and 750,000 SNP molecular markers. The standard
protocol incorporates the following eight procedures
before scanning the chip: genomic DNA digestion, NSP
adapter ligation, fragment amplification by PCR (Poly-
merase Chain Reaction), PCR product purification, PCR
product fragmentation, end-labeling, hybridization and
washing.
The Chromosome Analysis Suite software v1.2.1
(Affymetrix®) was used for the chip analysis.
Methylation status
For methylation analyses, the samples were subjected to
DNA modification using sodium bisulfite [24]. A fragment
with 22 CpGs of the CDH1 promoter region was amplified
using a nested PCR strategy [25]. Fragments obtained
were purified using PCR Purification Kit (Invitrogen/Life
Table 1 Primer sequences used in the study and their annealing temperatures
Exon Forward 5′- 3′ Reverse 5′- 3′ Tm (°C)
1 M13F GTGAACCCTCAGCCAATCAG M13R TGACGACGGGAGAGGAAG 63
2 M13F TGTTGGTTTCGGTGAGCAG M13R GGTGT3GGGAGTGCAATTTCT 61
3 M13F CGCTCTTTGGAGAAGGAATG M13R AACGGTACCAAGGCTGAGAA 58
4 M13F GCTGTCTGGCTAGGTTGGAC M13R TTTTCCCTTTCTCTCCTTGG 58
5 M13F GAAAGGGAAAAGACCCAGTG M13R GGATCCAGCATGGGTTGAC 58
6 M13F GCCCCTTCTCCCATGTTT M13R CTTTGGGCTTGGACAACACT 56
7 M13F GGGCAGAATTGGATTAAGCA M13R TGTCCACGGGATTGAGCTA 57
8 M13F CTGGGTAGGCCAAAGGT M13R CCATGAGCAGTGGTGACACTT 57
9 M13F AATCCTTTAGCCCCCTGAGA M13R AGGGGACAAGGGTATGAACA 61
10 M13F CCAAAAGCAACAGTTAAGGA M13R CAAATGACAAAATGCCATGA 56
11 M13F AGCGCTTAAGCCGTTTTCA M13R GAGGGGCAAGGAACTGAACT 60
12 M13F AAGGCAATGGGGATTCATTA M13R ATTGAAAGGTGGGGATCTGG 59
13 M13F CAATTTTATTCTGGAATGAGCTTTT M13R CAGGAAATAAACCTCCTCCATTT 55
14 M13F GCTGCTTCTGGCCTTCTTA M13R GCTGTTTCAAATGCCTACCTCT 55
15 M13F TGAACATAGCCCTGTGTGTATG M13R TTTTGACACAACTCCTCCTG 58
16 M13F AGACTTCTTGCCCCAGATGA M13R AACCACCAGCAACGTGATTT 63
Forward primers have – 21M13F tail attached for sequencing: TGTAAAACGACGGCCAGT; reverse primers have M13R tail attached for sequencing: CAGGAAACAGCTATGAC.
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an ABI3130 automatic sequencer (Applied Biosystems,
Foster City, CA, USA). The sequences were aligned with
BioEdit v7.0.5 [26]. Methylation analyses were run in BiQ
Analyzer [23] software.
Immunohistochemistry
An anti-cadherin (Abcam PLC, Cambridge, UK) com-
mercial primary antibody was used to detect the protein
product of the CDH1 gene (HDGC). Streptavidin-biotin-
peroxidase staining as described by Hsu et al. [27] was
adopted as the immunohistochemical method. The nor-
mality parameter was defined with samples from normal
(non-tumor) formalin-fixed and paraffin-embedded tis-
sues that had been obtained from routine samples. The
World Health Organization histopathological classifica-
tions for each tumor were used as well as the Lauren
classification for gastric cancer [28].
Results
The detailed patient data are shown in Table 2. A total
of 27 patient samples were collected for genetic analysis
from four unrelated families with histories of DGC in
northern and northeastern Brazil. All biological samples
collected were peripheral blood, except for the patient
AM05, whose sample was Paraffin-embedded tumor.
The sample comprised 18 men and nine women with a
mean age of 42 years and an age range of 20–75 years
(24–56 years for women and 20–75 years for men).
Of these 27 patients, nine (33.4%) had been previously
diagnosed with diffuse gastric cancer, whereas the remainingpatients did not have any type of gastric tumor. Among
the patients diagnosed with DGC, the age at diagnosis
ranged from 27–67 years.
After the retrospective study and using information
collected from the analyzed patients, it was possible to
identify relatives with a history of DGC and other types
of tumors (Figure 1).
Mutations in the CDH1 gene
Among the four families of patients, two families exhibited
germline mutations in the CDH1 gene, namely family A
from northern Brazil and family B from northeastern
Brazil (Table 3). In the other two families, which origi-
nated from northeastern Brazil, no mutations were found
in the evaluated CDH1 exons.
Array comparative genomic hybridization (aCGH)
The aCGH sample analysis showed no gains or losses of
DNA in the four tested families (27 samples).
Immunoreactivity in HDGC
CDH1 protein detection was performed only for patient
AM05, a carrier of the germline mutation 185 G > T and
member of family A. This patient died before the start of
the study, and a genetic analysis was performed on a
paraffin-embedded tumor tissue. The other study partici-
pants with this syndrome donated peripheral blood for
genetic analysis, and consequently, there was no need to
request paraffin blocks of the resected tumor tissues. The
tumor cells of patient AM05, revealed negative immuno-
reactivity to the E-cadherin protein.
Table 2 Identification of the patients analyzed in this
study
Patient Gender Age at diagnosis Type of cancer
(Family A)
^AM05 male 36 *DGC
AM06 female 56 none
AM07 male 31 *DGC
AM08 female 26 none
(Family B)
P05 male 29 *DGC
P06 male 27 *DGC
P07 male 23 none
P08 male 20 none
(Family C)
C05 male 75 Prostate
C14 male 52 *DGC
C15 male 50 *DGC
C16 female 49 *DGC
C17 female 48 none
C18 female 45 none
C19 female 47 none
C20 male 25 none
C21 male 23 none
C22 female 42 none
C23 female 24 none
C24 male 56 none
C25 male 35 none
C26 male 31 none
C27 male 58 none
C28 female 31 none
(Family D)
M08 female 67 *DGC
M09 male 62 *DGC
M10 male 64 none
^- Paraffin-embedded tumor sample.
* - Diffuse Gastric Cancer.
Moreira-Nunes et al. Hereditary Cancer in Clinical Practice 2014, 12:18 Page 4 of 8
http://www.hccpjournal.com/content/12/1/18Methylation status in HDGC
We analyzed the methylation pattern of a CDH1 gene
promoter region fragment in one CpG island containing
22 CpG dinucleotides, to find possible heritable epimuta-
tions. No promoter region hypermethylation was observed
in all 27 tested individuals, from the four families, and also
in 10 healthy controls.Discussion
In addition to sporadic manifestation, gastric cancer can
be associated with various syndromes that predisposethe carrier to cancer. Among the familial forms of gastric
cancer, HDGC is the only syndrome with a well-defined
genetic cause [2,3].
The relationship between a genetic germline mutation
in the E-cadherin-encoding gene (CDH1 inactivation)
and the predisposition to HDGC was first identified in a
family in New Zealand [6]. Based on this finding, the
HDGC syndrome was characterized, and other occur-
rences were described in patients with different ethnic
backgrounds [29].
Mutations in CDH1 gene affect protein integrity, thus
causing disturbances in cell-cell adhesion in epithelial
tissues, increasing cell motility and enhancing infiltrative
behavior of the tumor and metastasis development [10,11].
This genetic study of four families that carried the
HDGC syndrome allowed us to evaluate a previously
unaddressed issue within the Brazilian population. CDH1
germline mutations are observed in 30–40% of cases that
meet the clinical criteria for HDGC [30,31]. In our study,
50% of the families exhibited CDH1 gene mutations. This
information is useful in clinical evaluations of patients
with family histories of HDGC because in addition to
prophylactic measures, the information facilitates moni-
toring aimed at identifying the occurrence of other tumors
such as lobular carcinomas of the breast; these types of
cancers had also been detected in members of the families
analyzed in this study [13,20,32].
The cases described in the literature demonstrate that
the most common CDH1 gene alterations associated with
HDGC are point mutations and small changes in the read-
ing frame; these occur in approximately 93% of families
with CDH1 gene mutations [13,20,33].
In this study, two individuals in family A, a father and
son (Figure 1A), were carriers of a familial CDH1 gene
mutation at nucleotide position 185 (185G > T); this
mutation causes a change in the protein structure from
the amino acid glycine to valine. This missense mutation
was first described by Shinmura et al. [34] in a family of
Japanese origin. Our results suggest the hypothesis that
this 185G > T mutation was introduced into family A by
the grandfather of the proband (first generation pedigree),
who was of Japanese origin, and suggest that this mutation
might result from this ethnic background.
A CDH1 gene germline mutation was also identified in
two brothers from family B who had developed an early
form of gastric cancer (before 45 years of age) [35]. The
mutation was identified at nucleotide position 1018
(1018A > G) and resulted in a change from the amino
acid threonine to alanine. The 1018A > G mutation
was previously described in a family of European origin
and in a Chinese family [36,37]. Because the proband
of this family was of Portuguese descent, it is possible
that their ancestors brought this mutation to Brazil upon
immigration. On the other hand, another alternative to
Figure 1 Pedigrees of hereditary diffuse gastric cancer families. (A), (B), (C) and (D) represents the four families presented in this study. The
numbers present under the symbols represent the age at diagnosis. The solid symbols represent the affected members with confirmed diffuse
gastric cancer diagnoses. Upper left arrows indicate the probands.
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ent CDH1 locations to mutations.
A literature review revealed the occurrence of a total
of 122 germline mutations in the CDH1 gene in HDGC
[38]. Although several types of mutations have been
detected in different families, no hotspot has been
characterized to date [3,13]; this led us to sequence all
16 exons of the gene in the 30 members of the four
analyzed families.
Of the mutations reported in the literature, approxi-
mately 15% are shared by many families worldwide,
suggesting that CDH1 mutation-associated HDGC might
share a common ancestry, as was suggested for families A
and B in this study [33,39].Table 3 Germline CDH1 mutations identified in hereditary dif
Family ID Patient ID Age at onset/sex Exon Ba
A AM05 36/male 3
AM07 31/male
B P05 29/male 8
P06 27/maleIn the other two families (C and D), in which the eval-
uated subjects carried no CDH1 gene mutations, there
were considerable numbers of HDGC-affected members
in different generations (Figure 1). Pinheiro et al. [20]
have proposed that many HDGC families carry some
mutations in non-exonic regulatory regions of CDH1 (or
in upstream regulators). Based on this, it may be possible
in the future to test families C and D, for allele-specific
loss on CDH1.
In other populations in which the incidence of gastric
cancer is high, there are also reports of HDGC-carrier
families with large numbers of affected individuals who
do not carry CDH1 gene germline mutations. This finding
might be consequent to exposure to environmental riskfuse gastric cancer families
se changes Amino acid change Mutation consequence
185 G > T Gly ⋄ Val Missense
1018 A > G Thr ⋄ Ala Missense
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ations in low-penetrance genes [40,41].
In a study conducted in southeastern Brazil on 88
patients with early gastric cancer, 16 of whom had familial
histories of gastric cancer, it was possible to detect changes
in the E-cadherin protein expression in 41 individuals
via immunohistochemical analysis. Although CDH1 gene
sequencing was not conducted to identify possible muta-
tions, the immunohistochemical analysis revealed the in-
volvement of CDH1 in the early development of gastric
cancer in a Brazilian population [42].
Because the CDH1 gene acts as a tumor suppressor,
other gene inactivation mechanisms of this gene besides
germline mutations in one allele should be investigated
to identify changes to the second allele in somatic cells
(second event of the Knudson hypothesis [43]), which
was not able to be done in the present work. Mechanisms
such as CDH1 gene deletion [33] and promoter region
hypermethylation [44], were investigated in germline from
those analyzed patients, because are also considered po-
tentially responsible for its inactivation.
Cytosine hypermethylation in the CpG dinucleotides
present within the CDH1 promoter region induces tran-
scriptional silencing [45] and might thus explain the lack
of E-cadherin immunoreactivity. However, analyses to
confirm the presence of CDH1 gene promoter region
hypermethylation in patients with HDGC have not been
conclusive. For example, studies by Li et al. [46] and
Concolino et al. [47] demonstrated CDH1 promoter
hypermethylation-mediated gene silencing in 53–57% of
patients with HDGC. Conversely, Wu et al. [48] reported
an absence of this phenomenon in 140 Chinese gastric
cancer patients with a familial history of HDGC.
The analyses conducted in the present study did not
detect CDH1 gene promoter region hypermethylation in
the families with HDGC syndrome. Our results reinforce
the theory put forth by Yamada et al. [19] who, after
analyzing 22 Japanese patients with early gastric cancer,
suggested that germline CDH1 promoter hypermethyla-
tion was not a predisposing factor of gastric cancer.
In addition to epigenetic alterations in the promoter
region, the CDH1 gene might also suffer deletions even
in the absence of point mutations in the germlines of
patients with HDGC [49]. Kim et al. [50] used multiplex
ligation-dependent probe amplification (MLPA) to analyze
23 patients with HDGC and, similarly to our study, found
no deletions or duplications in these genes.
Oliveira et al. [33] genetically analyzed 160 patients
with HDGC from different geographic regions and found
that CDH1 gene deletions occurred in the peripheral
blood in approximately 4% of families affected by this syn-
drome. The same authors also observed that all families
with CDH1 deletions originated from countries with low
gastric cancer incidence rates. A large number of patientswith HDGC, in northern and northeastern from Brazil,
needs to be analyzed to verify if the absence of CDH1 gene
deletions and other quantitative genomic alterations,
as found in patients of this work, corroborate this
observation because these regions have high gastric
cancer incidence rates.
It is widely known that the most common forms of
cancer develop as a result of interactions between en-
dogenous and environmental factors such as the diet
[51]. Environmental factors might be related to the
high incidence of these neoplasms in the northern and
northeastern regions, or for some reason the HDGC
frequency is higher than elsewhere in the world, where
sporadic gastric cancer is also endemic, such as Japan
and Korea. In particular, Helicobacter pylori (H. pylori)
infection during childhood as well as the high consump-
tion of salt-preserved foods, infrequent use of refrigeration
and low consumption rates of cereals, fresh fruits and
vegetables are considered risk factors for gastrointestinal
tumors [52-55].
Conclusions
This is the first study to evaluate CDH1 gene germline
mutations and quantitative gene alterations in Brazilian
families with HDGC. CDH1 gene germline mutations
were found in 50% of the families evaluated. The detected
mutations appeared to originate from Asia and Europe.
This migratory flow does not rule out the possibility that
environmental factors might have caused these same mu-
tations in the affected members of the analyzed families.
No quantitative changes were observed in the genomes of
any of the analyzed families. It is possible that in regions
with high gastric cancer incidence rates such as northern
and northeastern Brazil, environmental factors or other
molecular mechanisms might induce different genetic
alterations from those analyzed in this study.
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